Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma

NCT03937830 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

27

Enrollment

NIH

Sponsor class

Conditions

Hepatocellular Cancer
Hepatocellular Carcinoma
Metastatic Hepatocellular Carcinoma

Interventions

DRUG: durvalumab
DRUG: Doxorubicin-Eluting Beads
PROCEDURE: TACE
DRUG: bevacizumab
DRUG: Tremelimumab

Sponsor

National Cancer Institute (NCI)